Activated C-SRC in Ductal Carcinoma in Situ Correlates with High Tumour Grade, High Proliferation and HER2 Positivity

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Oct 25

PMID 17060931

Citations 35

Authors

G R Wilson

A Cramer

A Welman

F Knox

R Swindell

H Kawakatsu

R B Clarke

C Dive

N J Bundred

Affiliations

Soon will be listed here.

Abstract

Overexpression and/or activity of c-Src non-receptor tyrosine kinase is associated with progression of several human epithelial cancers including breast cancer. c-Src activity in 'pure' ductal carcinoma in situ (DCIS) was measured to assess whether this predicts recurrence and/or correlates with HER2 expression and other clinical parameters. Activated c-Src levels were evaluated in DCIS biopsies from 129 women, with median follow-up at 60 months. High levels of activated c-Src correlated with HER2 positivity, high tumour grade, comedo necrosis and elevated epithelial proliferation. In univariate analysis, high activated c-Src level associated with lower recurrence-free survival at 5 years (P=0.011). Thus, high c-Src activity may identify a subset of DCIS with high risk of recurrence or progression to invasive cancer where therapeutics targeting c-Src may benefit this patient subset.

Citing Articles

Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.

Mustafayev F, Liu D, Gutierrez A, Lewis J, Ibrahim N, Valero V Eur J Breast Health. 2023; 19(4):267-273.

PMID: 37795002 PMC: 10546803. DOI: 10.4274/ejbh.galenos.2023.2023-7-3.

Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.

Nandi I, Smith H, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V J Clin Invest. 2023; 133(7).

PMID: 36795481 PMC: 10065076. DOI: 10.1172/JCI162324.

SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.

Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C Breast Cancer Res. 2022; 24(1):99.

PMID: 36581908 PMC: 9798727. DOI: 10.1186/s13058-022-01596-y.

Downregulation of Src-family tyrosine kinases by Srcasm and c-Cbl: A comparative analysis.

Lee V, Griffin T, Suzuki-Horiuchi Y, Wushanley L, Kweon Y, Marshall C J Carcinog. 2021; 20:21.

PMID: 34729053 PMC: 8531571. DOI: 10.4103/jcar.jcar_13_21.

State-selective frustration as a key driver of allosteric pluripotency.

Byun J, VanSchouwen B, Parikh N, Akimoto M, McNicholl E, Melacini G Chem Sci. 2021; 12(34):11565-11575.

PMID: 34667558 PMC: 8447923. DOI: 10.1039/d1sc01753e.

References

Irby R, Yeatman T . Role of Src expression and activation in human cancer. Oncogene. 2000; 19(49):5636-42. DOI: 10.1038/sj.onc.1203912. View

Planas-Silva M, Bruggeman R, Grenko R, Smith J . Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun. 2006; 341(1):73-81. DOI: 10.1016/j.bbrc.2005.12.164. View

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

Frame M . Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002; 1602(2):114-30. DOI: 10.1016/s0304-419x(02)00040-9. View

Ito Y, Kawakatsu H, Takeda T, Tani N, Kawaguchi N, Noguchi S . Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res Treat. 2002; 76(3):261-7. DOI: 10.1023/a:1020860221099. View

Myoui A, Nishimura R, Williams P, Hiraga T, Tamura D, Michigami T . C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003; 63(16):5028-33. View

Boland G, Butt I, Prasad R, Knox W, Bundred N . COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004; 90(2):423-9. PMC: 2409574. DOI: 10.1038/sj.bjc.6601534. View

Frame M . Newest findings on the oldest oncogene; how activated src does it. J Cell Sci. 2004; 117(Pt 7):989-98. DOI: 10.1242/jcs.01111. View

Yeatman T . A renaissance for SRC. Nat Rev Cancer. 2004; 4(6):470-80. DOI: 10.1038/nrc1366. View

10.

Jacobs C, Rubsamen H . Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 1983; 43(4):1696-702. View

11.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

12.

Rijksen G, van Beurden E, Hennipman A, Michels A, Staal G . Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 1992; 52(17):4773-8. View

13.

Muthuswamy S, Siegel P, Dankort D, Webster M, Muller W . Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol. 1994; 14(1):735-43. PMC: 358422. DOI: 10.1128/mcb.14.1.735-743.1994. View

14.

Guy C, Muthuswamy S, Cardiff R, Soriano P, Muller W . Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. 1994; 8(1):23-32. DOI: 10.1101/gad.8.1.23. View

15.

Muthuswamy S, Muller W . Activation of the Src family of tyrosine kinases in mammary tumorigenesis. Adv Cancer Res. 1994; 64:111-23. DOI: 10.1016/s0065-230x(08)60836-2. View

16.

Kawakatsu H, Sakai T, Takagaki Y, Shinoda Y, Saito M, Owada M . A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase. J Biol Chem. 1996; 271(10):5680-5. DOI: 10.1074/jbc.271.10.5680. View

17.

Verbeek B, Vroom T, Geertzema J, Hennipman A, Rijksen G . c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol. 1996; 180(4):383-8. DOI: 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N. View

18.

Sheffield L . C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells. Biochem Biophys Res Commun. 1998; 250(1):27-31. DOI: 10.1006/bbrc.1998.9214. View

19.

Noritake H, Miyamori H, Goto C, Seiki M, Sato H . Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src. Clin Exp Metastasis. 1999; 17(2):105-10. DOI: 10.1023/a:1006596620406. View

20.

Fisher E, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S . Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999; 86(3):429-38. DOI: 10.1002/(sici)1097-0142(19990801)86:3<429::aid-cncr11>3.0.co;2-y. View